Skip to main content
Clinical Trials/NCT04443218
NCT04443218
Completed
Not Applicable

Edwards PASCAL Transcatheter Valve Repair System Registry: A Multicenter Observational Registry With the Edwards PASCAL Transcatheter Valve Repair System

Edwards Lifesciences14 sites in 2 countries220 target enrollmentMay 27, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Mitral Valve Insufficiency
Sponsor
Edwards Lifesciences
Enrollment
220
Locations
14
Primary Endpoint
Major Adverse Events (MAEs)
Status
Completed
Last Updated
last year

Overview

Brief Summary

This registry will collect prospective and retrospective clinical data on patients treated with the Edwards PASCAL Transcatheter Valve Repair System outside of the Post-Market Clinical Follow-up (PMCF) study.

Detailed Description

Patients treated per standard of care at their medical facilities and a written informed consent will be collected to allow the data to be collected. This registry intends to enroll patients under commercial usage and will serve as a mechanism to collect clinical data to further characterize the safety, performance and effectiveness of the PASCAL Transcatheter Valve Repair System.

Registry
clinicaltrials.gov
Start Date
May 27, 2019
End Date
May 10, 2021
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Edwards Lifesciences
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient signs informed consent to participate in the registry
  • Patient is intended to or has received the PASCAL device

Exclusion Criteria

  • Patient does not consent to participate
  • Patient is part of an ongoing Edwards Pre or Post Market Clinical study for the PASCAL Transcatheter Valve Repair System.

Outcomes

Primary Outcomes

Major Adverse Events (MAEs)

Time Frame: 30 days

Composite rate of all-cause death, myocardial infarction, stroke, heart failure hospitalization, or complication requiring transcatheter or surgical intervention (repeat transcatheter edge-to-edge repair \[TEER\] or mitral valve surgery)

Mitral Regurgitation (MR) Reduction to <=2+

Time Frame: 30 days, 12 months

MR severity assessed by sites using a 5-grade scale: none/trace (0-1+), mild (1+), mild to moderate (2+), moderate to severe (3+), and severe (4+).

Secondary Outcomes

  • 6-Minute Walk Test (6MWT)(Baseline, 30 days, 12 months)
  • New York Heart Association (NYHA) Functional Classification(Baseline, 30 days, 12 months)
  • Quality of Life, as Assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Scores(Baseline, 30 days, 12 months)
  • Quality of Life, as Assessed by EQ-5D Visual Analog Scale (VAS)(Baseline, 30 days, 12 months)

Study Sites (14)

Loading locations...

Similar Trials